Perrigo

Opill and WNBA Team Up for Groundbreaking Partnership

Retrieved on: 
Tuesday, April 9, 2024
Consumer, National Basketball Association, Organization, Birth, Sport, Health equity, Social justice, Partnership, Pharmacy, Draft, NBA scoring leaders, Student, Perrigo, OTC, WNBA draft, WNBA, FDA, Health education, Food

GRAND RAPIDS, Mich. and NEW YORK, April 9, 2024 /PRNewswire/ -- Today, Perrigo Company plc, a leading provider of Consumer Self-Care Products, announced that Opill® — the first-ever daily birth control pill available without a prescription in the U.S. — and the Women's National Basketball Association (WNBA) have entered a multi-year partnership that focuses on building confidence, strength and health equity, all of which closely align with both organizations' core priorities.

Key Points: 
  • "Opill® is changing the game in reproductive health, just like the WNBA's game-changing role in sports and pop culture," said Leila Bahbah, Perrigo U.S. Women's Health Brand Lead.
  • Opill® will tip off the relationship as an Associate Partner of the 2024 WNBA Draft presented by State Farm on April 15 in Brooklyn, New York.
  • This season, the WNBA is concentrating its social justice efforts into two areas: civic engagement and reproductive health advocacy.
  • Opill® and the WNBA are also collaborating on a program to reach students on college campuses nationwide.

Ardelyx Appoints Veteran BioPharma Executive, Mike Kelliher, as Executive Vice President, Corporate Development and Strategy

Retrieved on: 
Monday, March 25, 2024
Biotechnology, Growth, Associated, Horizon Therapeutics, Executive, Patient, Business development, Acquisition, Élan, Inflammation, University College Cork, Commerce, Perrigo, Investment, Corporate development, Autoimmunity, Management

“This newly created position reflects the important inflection point at which we at Ardelyx find ourselves: Envisioning and building our future following the successful launch of two first-in-class medicines within the past two years,” said Mike Raab, president and chief executive officer of Ardelyx.

Key Points: 
  • “This newly created position reflects the important inflection point at which we at Ardelyx find ourselves: Envisioning and building our future following the successful launch of two first-in-class medicines within the past two years,” said Mike Raab, president and chief executive officer of Ardelyx.
  • “It is a pleasure to welcome Mike at this critical period of our growth.
  • His experience and expertise defining and advancing corporate strategies along with his proven track record of delivering value-accretive collaborations and transactions strengthen our leadership team and position us for success.
  • Mr. Kelliher began his career in banking, public accounting and corporate finance and holds a Bachelor of Commerce degree from the University College Cork (Ireland).

As Opill Enhances Women's Reproductive Choices Dr. Mary Jane Minkin Highlights Key Differences Between the Progesterone-Only Opill and Traditional Estrogen-Based Contraceptives “The Pill”

Retrieved on: 
Monday, March 11, 2024
Health, FDA, Consumer, Women, Baby, Maternity, General Health, Pharmaceutical, Mother, Birth, Education, OBGYN, Combined oral contraceptive pill, Condom, Risk, Diabetes, Ovulation, Stroke, History, Sale, News, Fertility, Splenic infarction, Smoke, Perrigo, Woman, OTC, Pill, Cancer, Breast cancer, Safety, Progesterone, MUST, Migraine, Birth control

Progesterone-only pills or “mini pills’ are usually used for nursing mothers and those unable to take estrogen-based contraceptives for health reasons and individual medical history.

Key Points: 
  • Progesterone-only pills or “mini pills’ are usually used for nursing mothers and those unable to take estrogen-based contraceptives for health reasons and individual medical history.
  • "Education is key at this juncture to prevent an increase in unintended pregnancies in the coming months.
  • The Opill, significantly differs from the traditional birth control pill in that it is less effective at preventing ovulation when pills are missed or skipped for any reason.
  • The availability of the Opill OTC, or progesterone-only pill, is wonderful news for those women unable to take estrogen or 'The Pill.'

Lutris Pharma Appoints Life Sciences and Pharmaceutical Entrepreneur Moshe "Mori" Arkin to Its Board of Directors

Retrieved on: 
Monday, April 1, 2024
Culture, EGFR, Organization, Philosophy, Education, History, Patient, Orphan, Left–right political spectrum, Growth factor, Acquisition, Perrigo, Quality of life, Psychology, Drug development, TEL, Food, Pharmaceutical industry

TEL AVIV, Israel, April 1, 2024 /PRNewswire/ -- Lutris Pharma , a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing dose limiting side effects, today announced the appointment Moshe "Mori" Arkin, a life sciences and pharmaceutical entrepreneur, and Founder and Chairman of Arkin Holdings, to its Board of Directors.

Key Points: 
  • TEL AVIV, Israel, April 1, 2024 /PRNewswire/ -- Lutris Pharma , a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing dose limiting side effects, today announced the appointment Moshe "Mori" Arkin, a life sciences and pharmaceutical entrepreneur, and Founder and Chairman of Arkin Holdings, to its Board of Directors.
  • "Mori is one of Israel's most successful life sciences and pharmaceutical entrepreneurs with an extraordinary background spanning decades in the industry," stated Antoni Ribas, M.D., Ph.D., Chairman and Founder of Lutris Pharma.
  • "Arkin Bio Ventures has been an investor in Lutris Pharma since its inception and has been a steadfast supporter of the Company, ever since.
  • In 2011, they formed the Arkin Family Foundation, which supports organizations and projects in education, arts and culture, welfare, healthcare, civil rights, and Jewish-Arab coexistence.

Lutris Pharma Appoints Life Sciences and Pharmaceutical Entrepreneur Moshe "Mori" Arkin to Its Board of Directors

Retrieved on: 
Monday, April 1, 2024
Culture, EGFR, Organization, Philosophy, Education, History, Patient, Orphan, Left–right political spectrum, Growth factor, Acquisition, Perrigo, Quality of life, Psychology, Drug development, TEL, Food, Pharmaceutical industry

TEL AVIV, Israel, April 1, 2024 /PRNewswire/ -- Lutris Pharma , a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing dose limiting side effects, today announced the appointment Moshe "Mori" Arkin, a life sciences and pharmaceutical entrepreneur, and Founder and Chairman of Arkin Holdings, to its Board of Directors.

Key Points: 
  • TEL AVIV, Israel, April 1, 2024 /PRNewswire/ -- Lutris Pharma , a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing dose limiting side effects, today announced the appointment Moshe "Mori" Arkin, a life sciences and pharmaceutical entrepreneur, and Founder and Chairman of Arkin Holdings, to its Board of Directors.
  • "Mori is one of Israel's most successful life sciences and pharmaceutical entrepreneurs with an extraordinary background spanning decades in the industry," stated Antoni Ribas, M.D., Ph.D., Chairman and Founder of Lutris Pharma.
  • "Arkin Bio Ventures has been an investor in Lutris Pharma since its inception and has been a steadfast supporter of the Company, ever since.
  • In 2011, they formed the Arkin Family Foundation, which supports organizations and projects in education, arts and culture, welfare, healthcare, civil rights, and Jewish-Arab coexistence.

Perrigo Commences Shipments of Opill® to Retailers Nationwide, Empowering Millions to Enter a New Era of Reproductive Health Access in the United States

Retrieved on: 
Monday, March 4, 2024
Melissa, Woman, FDA, OTC, Perrigo, Food, Transport, Family medicine, Pharmacy, MBA, Health savings account, American Medical Association, Pregnancy, FSA, Health, HSA, American College, MPH, Consumer, MSRP, PRGO, American Academy, Birth control

Additionally, Opill® will be available for purchase at Opill.com at a price of $49.99 for a three-month supply and $89.99 for a six-month supply.

Key Points: 
  • Additionally, Opill® will be available for purchase at Opill.com at a price of $49.99 for a three-month supply and $89.99 for a six-month supply.
  • "The availability of an oral contraceptive without a prescription is a truly groundbreaking milestone in reproductive health," said Melissa J. Kottke, MD, MPH, MBA, obstetrician-gynecologist in Atlanta, GA*.
  • Creating additional opportunities for contraceptive access is critical in helping people reach their reproductive goals."
  • * Melissa J. Kottke, MD, MPH, MBA served as a paid consultant during the FDA approval process for Perrigo in 2023.

Perrigo to Attend UBS Global Consumer and Retail Conference

Retrieved on: 
Thursday, February 29, 2024
Perrigo, Consumer, PRGO, Conference

DUBLIN, Feb. 29, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that President and CEO Patrick Lockwood-Taylor and CFO Eduardo Bezerra are scheduled to present at the UBS Global Consumer and Retail Conference in New York City on Wednesday, March 13th at 4:00 PM EST.

Key Points: 
  • DUBLIN, Feb. 29, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that President and CEO Patrick Lockwood-Taylor and CFO Eduardo Bezerra are scheduled to present at the UBS Global Consumer and Retail Conference in New York City on Wednesday, March 13th at 4:00 PM EST.

Perrigo to Release Fourth Quarter and Fiscal Year 2023 Financial Results on February 27, 2024

Retrieved on: 
Tuesday, February 13, 2024
Perrigo, International, EST, Consumer, ID, PRGO

DUBLIN, Feb. 13, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that it plans to issue its fourth quarter and fiscal year 2023 financial results on Tuesday, February 27th, 2024 and will host a conference call beginning at 8:30 A.M. (EST).

Key Points: 
  • DUBLIN, Feb. 13, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that it plans to issue its fourth quarter and fiscal year 2023 financial results on Tuesday, February 27th, 2024 and will host a conference call beginning at 8:30 A.M. (EST).
  • The earnings conference call will be available live via webcast to interested parties in the investor relations section of the Perrigo website at http://perrigo.investorroom.com/events-webcasts or by phone at 888-664-6383, International 617-892-4906, and reference ID # 73063681.
  • A taped replay of the call will be available beginning at approximately 12:00 P.M. (EST) Tuesday, February 27, until midnight Tuesday, March 05, 2024.
  • To listen to the replay, dial 888-390-0541, International 416-764-8677, and use access code 063681#.

Firefly® Donates 775,000 Toothbrushes to Baby2Baby in honor of Giving Tuesday

Retrieved on: 
Tuesday, November 28, 2023
Poverty, Time (magazine), TIME, Health, Hospital, Imagination, School, Clothing, Perrigo, Habit, Firefly, Pharmaceutical industry, Toy

Firefly donates 775,000 toothbrushes to Baby2Baby, improving children's lives with basic necessities they need & deserve

Key Points: 
  • Firefly donates 775,000 toothbrushes to Baby2Baby, improving children's lives with basic necessities they need & deserve
    Firefly® is known for its innovative portfolio of oral care products, including brushes, rinses, and pastes designed to encourage healthy habits in children.
  • By incorporating imagination, fun, and games into the bathroom experience, Firefly® ensures that developing these habits is not only educational but also enjoyable.
  • Their products feature dazzling light-up elements, vibrant flavors, and beloved characters, making oral care engaging and fun for kids.
  • Our donation of 775,000 toothbrushes underscores our dedication to improving children's lives and fostering healthy habits from a young age.

Masimo Announces New Member of the Board of Directors

Retrieved on: 
Tuesday, November 7, 2023
Medical Devices, Health, Technology, Health Technology, Cardiology, Auxilium, Pharmacia, Mayo Collaborative Services v. Prometheus Laboratories, Inc., BICO Group, Catalent, Chemical engineering, MASI, Chemical substance, Vice, Business, Perrigo, Central Executive Committee of the Pakistan Peoples Party, Merck Millipore, Supervisory board, Gothenburg University Library, Executive Committee, University of Gothenburg, Gothenburg School of Business, Economics and Law, Retirement, Management, Engineering

Masimo (NASDAQ: MASI) announced today that Rolf A. Classon has been appointed to Masimo’s Board of Directors.

Key Points: 
  • Masimo (NASDAQ: MASI) announced today that Rolf A. Classon has been appointed to Masimo’s Board of Directors.
  • Mr. Classon is an experienced medical technology executive and board member.
  • Mr. Classon was previously Chairman of the Board of Directors of Perrigo Company plc, Chairman of the Board of Directors of Tecan Group Ltd., Chairman of the Board of Directors of Hill-Rom Corporation, and Chairman of the Board of Directors of Auxilium Pharmaceuticals, Inc.
  • Joe Kiani, Chairman and CEO of Masimo, said, “We’re happy to welcome Rolf to our Board.